Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

es generated from exenatide may be affected by competition, unexpected new data, technical issues, clinical trials not confirming previous results or predicting future results, label expansion requests not being submitted in a timely manner or receiving regulatory approval, or manufacturing and supply issues. The potential for exenatide may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin and Lilly's most recently filed United States Securities Exchange Commission documents such as their Quarterly Reports on Form 10-Q. Amylin and Lilly undertake no duty to update these forward-looking statements.

P-LLY

REFERENCES

1 Bunck MC, Diamant MA, Corner EB, Malloy JL, Shaginian RM, Deng W,

Kendall DM, Taskinen MR, Smith U, Yki-Jarvinen H, and Heine RJ. One

year treatment with exenatide improves beta-cell function and glycaemic

control in metformin treated type 2 diabetes patients. Control/Tracking

Number: A-07-175-EASD.

2 "Definition of C-peptide." MedicineNet.com. Available at

http://www.medterms.com/script/main/art.asp?articlekey=12467. Accessed

July 25, 2007.

3 Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P,

Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment

of insulin secretion and insulin sensitivity using a hyperglycemia

clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382.

4 The International Diabetes Federation Diabetes Atlas. Available at:

http://www.idf.org/home/index.cfm
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... in regulating appetite and whole-body metabolism. A protein known ... food intake and body weight, but the identity of ... A new study in the Journal of ... type of neuron known as pro-opiomelanocortin (POMC) neurons is ... Sabrina Diano and colleagues at Yale University School of ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... obese and work in manufacturing jobs may have significantly less endurance ... a study of 32 people -- half were obese, half were ... times that were about 60 percent longer. Obesity also was ... Being older -- 50 to 65 years of ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- The U.S. Food and ... new drug, Jardiance, to help fight type 2 diabetes. ... added to existing treatment regimens to control blood sugar ... Rosebraugh, director of the Office of Drug Evaluation II ... said in an agency statement. The FDA also ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... and areas for improvement in reform proposals for small businesses ... on Small Business and Entrepreneurship Chair Mary Landrieu, D-La., and ... to better understand the needs of small businesses in health ... those needs. , "We are here today to discuss one ...
... , WASHINGTON, Oct. 20 Speaker Nancy Pelosi, House ... Michigan held a press availability this afternoon ... the urgency of health insurance reform for children with pre-existing ... and Jessica Segal of Texas told ...
... benefits patients, study shows , TUESDAY, Oct. 20 (HealthDay ... patients when used up to 4.5 hours after a ... provide further evidence to increase the tPA treatment window ... Previously published findings from the ECASS III study indicated ...
... 20 (HealthDay News) -- In an effort to reduce ... Reproductive Medicine has revised its recommendations on the number ... fertilization procedures. , The society reports that the ... For one, it says that doctors should only use ...
... Body Worlds 2 & The Brain ... October 17, and will be one of many points of ... of scientific treasures. The second-largest medical research and education center ... medical, anatomical and scientific sites--from the nation,s first hospital and ...
... patients in U.S. hospitals fail to get recommended therapy, ... A recommended treatment for heart failure is underused in ... of aldosterone antagonist therapy in patients with heart failure ... failure guidelines established by the American College of ...
Cached Medicine News:Health News:Landrieu, Snowe Champion Small Business Health Care Reform Efforts 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 3Health News:Stroke Treatment Window May Allow a Bit More Time 2Health News:New IVF Guidelines Aim to Reduce Multiple Births 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 3Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 4Health News:Heart Failure Treatment Underused 2
... SG-2002 Stand-Alone Ganzfeld produces ... stimuli, which will elicit ... be amplified and recorded. ... is painted with a ...
... crescent-shaped interbody spacer used to provide anterior ... is available in either titanium or PEEK-OPTIMA, ... TraXis is implanted through a posterolateral approach ... and then curved across the midline to ...
... LKCs Sweep VEP technology is designed for productivity ... in conjunction with doctors from the University of ... over a decade on over 5,000 subjects. All ... be set and stored, or can be preset ...
... ALL-NEW CV-3000 Computerized Vision Tester offers ... and expands the many features of ... demand for delegating the refraction, electronic ... to generate an incredible interest in ...
Medicine Products: